Febuxostat use is associated with a significantly greater risk of mild to moderate perturbation of liver function compared to benzbromarone in patients with gout: comment on the article by Sun et al

Documenti analoghi

• Risk of hepatotoxicity in use of febuxostat or benzbromarone: comment on the article by Sun et al
  di: Shih‐Wei Lai, et al.
  Pubblicazione: (2025)
• Lower environmental temperature and higher relative humidity had significant associations with worsened Raynaud phenomenon in systemic sclerosis: comment on the article by Taylor et al
  di: Gang Wang, et al.
  Pubblicazione: (2025)
• Lower or higher 25‐hydroxyvitamin D levels associated with adverse pregnancy outcomes: comment on the article by Madanchi et al
  di: Gang Wang, et al.
  Pubblicazione: (2025)
• Methodologic and conceptual limitations in moderator and mediator analyses of knee osteoarthritis trials: comment on the article by Farivar et al
  di: Yao Liu, et al.
  Pubblicazione: (2026)
• Pain sensitivity and chronic pain as a link between analgesic use and cardiovascular/gastrointestinal risk: comment on the article by Kaur et al
  di: Ryuichi Minoda Sada
  Pubblicazione: (2025)